Johannesburg: Johnson & Johnson has announced that new preliminary results from a South African study has shown that the homologous booster shot of the company’s Covid-19 vaccine (Ad26.COV2.S) demonstrated 85 per cent effectiveness against the virus-related hospitalisation in South Africa after Omicron became the dominant variant. The South African Phase 3b Sisonke study, conducted by […]